Sarepta Reiterated Total Net Product Revenue of $3.0 Billion in 2025
As children and families battling Duchenne Muscular Dystrophy wait for drug prices to drop, Sarepta has announced its earnings forecast for 2025. How much...
Wave Life Sciences Announces Plans for Exon 53 Skipping Study in 2025
Alpha-1 antitrypsin deficiency (AATD), Huntington's disease (HD), obesity, and Duchenne muscular dystrophy (DMD) are among the major unmet medical needs that the company seeks...
Edgewise Therapeutics Announces Plans for 2025
Edgewise Therapeutics has announced its 2025 plans for Duchenne muscular dystrophy. The company said in a statement that it will prioritize Sevasemten.
Sevasemten is an...
Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics
Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy...
Avidity Biosciences Prepares for Three Rare Muscle Disease Programs’ 2025 BLA Submission and Commercialization
A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its...